Matrix metalloproteinases (MMPs) are involved in the normal processes
of tissue remodelling and repair, but have increasingly been implicate
d in a range of disease states where they are over-expressed. This rev
iew summarises developments in the design and clinical evaluation of s
ynthetic MMP inhibitors since the subject was last covered in this jou
rnal in 1995.